Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 284 entries
Sorted by: Best Match Show Resources per page
Is there a role for combinations of antiplatelet agents in stroke prevention?.

Current treatment options in neurology

Schwartz NE, Albers GW.
PMID: 18173943
Curr Treat Options Neurol. 2007 Nov;9(6):442-50. doi: 10.1007/s11940-007-0045-y.

Antiplatelet medications are the agents of choice for secondary prevention of noncardioembolic ischemic strokes. Multiple clinical trials have proven their reliable albeit modest clinical benefits and relatively good safety profile. The most commonly recommended antiplatelet agents for secondary stroke...

Cite
Schwartz NE, Albers GW. Is there a role for combinations of antiplatelet agents in stroke prevention?. Curr Treat Options Neurol. 2007;9(6):442-50doi: 10.1007/s11940-007-0045-y.
Schwartz, N. E., & Albers, G. W. (2007). Is there a role for combinations of antiplatelet agents in stroke prevention?. Current treatment options in neurology, 9(6), 442-50. https://doi.org/10.1007/s11940-007-0045-y
Schwartz, Neil E, and Albers, Gregory W. "Is there a role for combinations of antiplatelet agents in stroke prevention?." Current treatment options in neurology vol. 9,6 (2007): 442-50. doi: https://doi.org/10.1007/s11940-007-0045-y
Schwartz NE, Albers GW. Is there a role for combinations of antiplatelet agents in stroke prevention?. Curr Treat Options Neurol. 2007 Nov;9(6):442-50. doi: 10.1007/s11940-007-0045-y. PMID: 18173943.
Copy Download .nbib Format: NLM
CTAD as a universal anticoagulant.

Journal of automated methods & management in chemistry

Yokota M, Tatsumi N, Tsuda I, Nishioka T, Takubo T.
PMID: 18924886
J Autom Methods Manag Chem. 2003;25(1):17-20. doi: 10.1155/S1463924603000038.

The feasibility of CTAD (a mixture of citrate, theophylline, adenosine and dipyridamole) as a new anticoagulant for medical laboratory use was studied prospectively. Whole blood anticoagulated with CTAD exhibited results very similar to those of blood anticoagulated with EDTA...

Cite
Yokota M, Tatsumi N, Tsuda I, et al. CTAD as a universal anticoagulant. J Autom Methods Manag Chem. 2003;25(1):17-20doi: 10.1155/S1463924603000038.
Yokota, M., Tatsumi, N., Tsuda, I., Nishioka, T., & Takubo, T. (2003). CTAD as a universal anticoagulant. Journal of automated methods & management in chemistry, 25(1), 17-20. https://doi.org/10.1155/S1463924603000038
Yokota, M, et al. "CTAD as a universal anticoagulant." Journal of automated methods & management in chemistry vol. 25,1 (2003): 17-20. doi: https://doi.org/10.1155/S1463924603000038
Yokota M, Tatsumi N, Tsuda I, Nishioka T, Takubo T. CTAD as a universal anticoagulant. J Autom Methods Manag Chem. 2003;25(1):17-20. doi: 10.1155/S1463924603000038. PMID: 18924886; PMCID: PMC2548379.
Copy Download .nbib Format: NLM
Commentary. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

Perspectives in vascular surgery and endovascular therapy

Sobel M.
PMID: 17437989
Perspect Vasc Surg Endovasc Ther. 2007 Mar;19(1):87-9. doi: 10.1177/1531003507299489.

No abstract available.

Cite
Sobel M. Commentary. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Perspect Vasc Surg Endovasc Ther. 2007;19(1):87-9doi: 10.1177/1531003507299489.
Sobel, M. (2007). Commentary. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Perspectives in vascular surgery and endovascular therapy, 19(1), 87-9. https://doi.org/10.1177/1531003507299489
Sobel, Michael. "Commentary. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial." Perspectives in vascular surgery and endovascular therapy vol. 19,1 (2007): 87-9. doi: https://doi.org/10.1177/1531003507299489
Sobel M. Commentary. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Perspect Vasc Surg Endovasc Ther. 2007 Mar;19(1):87-9. doi: 10.1177/1531003507299489. PMID: 17437989.
Copy Download .nbib Format: NLM
The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs.

Talanta

Issa AS, Mahrous MS, Salam MA, Soliman N.
PMID: 18964385
Talanta. 1987 Jul;34(7):670-2. doi: 10.1016/0039-9140(87)80087-5.

Some basic cardiovascular drugs containing secondary or tertiary amino groups are determined spectrophotometrically. The method is simple and sensitive; it is based on the interaction of the drugs, as n-electron donors, with 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) as a pi-acceptor. The highly...

Cite
Issa AS, Mahrous MS, Salam MA, et al. The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs. Talanta. 1987;34(7):670-2doi: 10.1016/0039-9140(87)80087-5.
Issa, A. S., Mahrous, M. S., Salam, M. A., & Soliman, N. (1987). The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs. Talanta, 34(7), 670-2. https://doi.org/10.1016/0039-9140(87)80087-5
Issa, A S, et al. "The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs." Talanta vol. 34,7 (1987): 670-2. doi: https://doi.org/10.1016/0039-9140(87)80087-5
Issa AS, Mahrous MS, Salam MA, Soliman N. The use of 2,3-dichloro-5,6-dicyano-p-benzoquinone for the spectrophotometric determination of some cardiovascular drugs. Talanta. 1987 Jul;34(7):670-2. doi: 10.1016/0039-9140(87)80087-5. PMID: 18964385.
Copy Download .nbib Format: NLM
Trace measurement of dipyridamole by adsorptive stripping voltammetry.

Talanta

Zeng X, Lin S, Hu N.
PMID: 18965766
Talanta. 1993 Aug;40(8):1183-7. doi: 10.1016/0039-9140(93)80185-t.

A sensitive adsorptive stripping voltammetric method for trace measurement of dipyridamole in alkaline solution is described. The method is based on the adsorptive accumulation of the drug at the hanging mercury drop electrode, followed by linear sweep voltammetric determination....

Cite
Zeng X, Lin S, Hu N. Trace measurement of dipyridamole by adsorptive stripping voltammetry. Talanta. 1993;40(8):1183-7doi: 10.1016/0039-9140(93)80185-t.
Zeng, X., Lin, S., & Hu, N. (1993). Trace measurement of dipyridamole by adsorptive stripping voltammetry. Talanta, 40(8), 1183-7. https://doi.org/10.1016/0039-9140(93)80185-t
Zeng, X, et al. "Trace measurement of dipyridamole by adsorptive stripping voltammetry." Talanta vol. 40,8 (1993): 1183-7. doi: https://doi.org/10.1016/0039-9140(93)80185-t
Zeng X, Lin S, Hu N. Trace measurement of dipyridamole by adsorptive stripping voltammetry. Talanta. 1993 Aug;40(8):1183-7. doi: 10.1016/0039-9140(93)80185-t. PMID: 18965766.
Copy Download .nbib Format: NLM
The therapeutic potential of agents acting via purine receptors.

Expert opinion on investigational drugs

Appleman JR, Erion MD.
PMID: 15991954
Expert Opin Investig Drugs. 1998 Feb;7(2):225-43. doi: 10.1517/13543784.7.2.225.

A host of physiological processes associated with the cardiovascular (CV) system, central nervous system (CNS), and a variety of other organ systems and tissues are regulated by agents, primarily adenosine (ado) and adenosine triphosphate (ATP), that act via cell-surface...

Cite
Appleman JR, Erion MD. The therapeutic potential of agents acting via purine receptors. Expert Opin Investig Drugs. 1998;7(2):225-43doi: 10.1517/13543784.7.2.225.
Appleman, J. R., & Erion, M. D. (1998). The therapeutic potential of agents acting via purine receptors. Expert opinion on investigational drugs, 7(2), 225-43. https://doi.org/10.1517/13543784.7.2.225
Appleman, J R, and Erion, M D. "The therapeutic potential of agents acting via purine receptors." Expert opinion on investigational drugs vol. 7,2 (1998): 225-43. doi: https://doi.org/10.1517/13543784.7.2.225
Appleman JR, Erion MD. The therapeutic potential of agents acting via purine receptors. Expert Opin Investig Drugs. 1998 Feb;7(2):225-43. doi: 10.1517/13543784.7.2.225. PMID: 15991954.
Copy Download .nbib Format: NLM
Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways.

Expert opinion on emerging drugs

Minamino T, Kitakaze M.
PMID: 15989539
Expert Opin Emerg Drugs. 2002 May;7(1):99-110. doi: 10.1517/14728214.7.1.99.

Accumulated evidence suggests that several drugs proven to improve survival in patients with chronic heart failure (CHF) enhance endogenous nitric oxide (NO)- and/or adenosine-dependent pathways. Indeed, we and others have demonstrated that: i) antagonists of either renin-angiotensin-aldosterone or beta-adrenergic...

Cite
Minamino T, Kitakaze M. Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways. Expert Opin Emerg Drugs. 2002;7(1):99-110doi: 10.1517/14728214.7.1.99.
Minamino, T., & Kitakaze, M. (2002). Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways. Expert opinion on emerging drugs, 7(1), 99-110. https://doi.org/10.1517/14728214.7.1.99
Minamino, Tetsuo, and Kitakaze, Masafumi. "Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways." Expert opinion on emerging drugs vol. 7,1 (2002): 99-110. doi: https://doi.org/10.1517/14728214.7.1.99
Minamino T, Kitakaze M. Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways. Expert Opin Emerg Drugs. 2002 May;7(1):99-110. doi: 10.1517/14728214.7.1.99. PMID: 15989539.
Copy Download .nbib Format: NLM
Harken caged-disc mitral valve replacement, 1969-1975: analysis of late mortality, thromboembolism, and valve failure.

Texas Heart Institute journal

Gray RJ, Czer LS, Chaux A, Sethna D, DeRobertis M, Raymond M, Matloff JM.
PMID: 15227298
Tex Heart Inst J. 1987 Dec;14(4):411-7.

We evaluated the long-term outcome of mitral valve replacement with a Harken caged-disc prosthesis for up to 11 years (range, 50 to 130 months; mean, 81 months) in 170 patients whose mean age was 55 years. The early (30-day)...

Cite
Gray RJ, Czer LS, Chaux A, et al. Harken caged-disc mitral valve replacement, 1969-1975: analysis of late mortality, thromboembolism, and valve failure. Tex Heart Inst J. 1987;14(4):411-7
Gray, R. J., Czer, L. S., Chaux, A., Sethna, D., DeRobertis, M., Raymond, M., & Matloff, J. M. (1987). Harken caged-disc mitral valve replacement, 1969-1975: analysis of late mortality, thromboembolism, and valve failure. Texas Heart Institute journal, 14(4), 411-7.
Gray, R J, et al. "Harken caged-disc mitral valve replacement, 1969-1975: analysis of late mortality, thromboembolism, and valve failure." Texas Heart Institute journal vol. 14,4 (1987): 411-7.
Gray RJ, Czer LS, Chaux A, Sethna D, DeRobertis M, Raymond M, Matloff JM. Harken caged-disc mitral valve replacement, 1969-1975: analysis of late mortality, thromboembolism, and valve failure. Tex Heart Inst J. 1987 Dec;14(4):411-7. PMID: 15227298; PMCID: PMC324766.
Copy Download .nbib Format: NLM
Antiplatelet agents for secondary prevention of stroke.

Current treatment options in cardiovascular medicine

Bernstein RA.
PMID: 18582411
Curr Treat Options Cardiovasc Med. 2008 Jun;10(3):223-8. doi: 10.1007/s11936-008-0024-y.

Patients with recent ischemic stroke or transient ischemic attack (TIA) face a high risk of recurrent stroke as well as an increased risk of myocardial infarction and sudden cardiac death. In the absence of a clearly established indication for...

Cite
Bernstein RA. Antiplatelet agents for secondary prevention of stroke. Curr Treat Options Cardiovasc Med. 2008;10(3):223-8doi: 10.1007/s11936-008-0024-y.
Bernstein, R. A. (2008). Antiplatelet agents for secondary prevention of stroke. Current treatment options in cardiovascular medicine, 10(3), 223-8. https://doi.org/10.1007/s11936-008-0024-y
Bernstein, Richard A. "Antiplatelet agents for secondary prevention of stroke." Current treatment options in cardiovascular medicine vol. 10,3 (2008): 223-8. doi: https://doi.org/10.1007/s11936-008-0024-y
Bernstein RA. Antiplatelet agents for secondary prevention of stroke. Curr Treat Options Cardiovasc Med. 2008 Jun;10(3):223-8. doi: 10.1007/s11936-008-0024-y. PMID: 18582411.
Copy Download .nbib Format: NLM
Regional distribution of adenosine uptake in guinea-pig brain slices and the effect of some inhibitors: Evidence for nitrobenzylthioinosine-sensitive and insensitive sites?.

Neurochemistry international

Davies LP, Hambley JW.
PMID: 20493035
Neurochem Int. 1986;8(1):103-8. doi: 10.1016/0197-0186(86)90106-3.

The accumulation of [2-(3)H]adenosine was measured in slices prepared from 7 regions of the guinea-pig central nervous system. There was a similar level of uptake in forebrain regions (cerebral cortex, striatum, hippocampus and midbrain), a lower level in the...

Cite
Davies LP, Hambley JW. Regional distribution of adenosine uptake in guinea-pig brain slices and the effect of some inhibitors: Evidence for nitrobenzylthioinosine-sensitive and insensitive sites?. Neurochem Int. 1986;8(1):103-8doi: 10.1016/0197-0186(86)90106-3.
Davies, L. P., & Hambley, J. W. (1986). Regional distribution of adenosine uptake in guinea-pig brain slices and the effect of some inhibitors: Evidence for nitrobenzylthioinosine-sensitive and insensitive sites?. Neurochemistry international, 8(1), 103-8. https://doi.org/10.1016/0197-0186(86)90106-3
Davies, L P, and Hambley, J W. "Regional distribution of adenosine uptake in guinea-pig brain slices and the effect of some inhibitors: Evidence for nitrobenzylthioinosine-sensitive and insensitive sites?." Neurochemistry international vol. 8,1 (1986): 103-8. doi: https://doi.org/10.1016/0197-0186(86)90106-3
Davies LP, Hambley JW. Regional distribution of adenosine uptake in guinea-pig brain slices and the effect of some inhibitors: Evidence for nitrobenzylthioinosine-sensitive and insensitive sites?. Neurochem Int. 1986;8(1):103-8. doi: 10.1016/0197-0186(86)90106-3. PMID: 20493035.
Copy Download .nbib Format: NLM
Dipyridamole and Platelet Release of Platelet-derived Growth Factor.

Platelets

Vissinger H, Husted SE, Kristensen SD, Nielsen HK.
PMID: 21043611
Platelets. 1994;5(2):105-8. doi: 10.3109/09537109409005520.

Platelet-derived growth factor (PDGF) and β-thromboglobulin (β-TG) are released from platelet alpha-granules during platelet activation. PDGF is a potent chemoattractant and mitogen for human vascular smooth muscle cells, and may be important in the development of late restenosis following...

Cite
Vissinger H, Husted SE, Kristensen SD, et al. Dipyridamole and Platelet Release of Platelet-derived Growth Factor. Platelets. 1994;5(2):105-8doi: 10.3109/09537109409005520.
Vissinger, H., Husted, S. E., Kristensen, S. D., & Nielsen, H. K. (1994). Dipyridamole and Platelet Release of Platelet-derived Growth Factor. Platelets, 5(2), 105-8. https://doi.org/10.3109/09537109409005520
Vissinger, H, et al. "Dipyridamole and Platelet Release of Platelet-derived Growth Factor." Platelets vol. 5,2 (1994): 105-8. doi: https://doi.org/10.3109/09537109409005520
Vissinger H, Husted SE, Kristensen SD, Nielsen HK. Dipyridamole and Platelet Release of Platelet-derived Growth Factor. Platelets. 1994;5(2):105-8. doi: 10.3109/09537109409005520. PMID: 21043611.
Copy Download .nbib Format: NLM
Dipyridamole in the Management of Severe Heparin-associated Thrombocytopenia.

Platelets

Al-Momen AK, Gader AM.
PMID: 21043885
Platelets. 1993;4(2):67-71. doi: 10.3109/09537109309013198.

Severe heparin-associated thrombocytopenia (SHAT) is a rare, life-threatening condition. The aim of this prospective pilot study was to determine the safety and efficacy of dipyridamole-heparin infusion (DHI) in the management of the condition. We studied 6 patients (4 males...

Cite
Al-Momen AK, Gader AM. Dipyridamole in the Management of Severe Heparin-associated Thrombocytopenia. Platelets. 1993;4(2):67-71doi: 10.3109/09537109309013198.
Al-Momen, A. K., & Gader, A. M. (1993). Dipyridamole in the Management of Severe Heparin-associated Thrombocytopenia. Platelets, 4(2), 67-71. https://doi.org/10.3109/09537109309013198
Al-Momen, A K, and Gader, A M. "Dipyridamole in the Management of Severe Heparin-associated Thrombocytopenia." Platelets vol. 4,2 (1993): 67-71. doi: https://doi.org/10.3109/09537109309013198
Al-Momen AK, Gader AM. Dipyridamole in the Management of Severe Heparin-associated Thrombocytopenia. Platelets. 1993;4(2):67-71. doi: 10.3109/09537109309013198. PMID: 21043885.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 284 entries